News & Press Releases

Of Counsel Michelle Capezza recently shared insights with Fiduciary News in light of the recent "Democratizing Access to Alternative Assets for 401(K) Investors" executive order. The article emphasizes that fiduciaries must respond quickly and carefully to new regulations, protecting participants while adapting to a more complex retirement landscape.

Member Marguerite McConihe was quoted by 9fin in an article about the opportunities and risks associated with the use of AI technologies in leveraged finance. The article notes that while LevFin bankers have largely benefitted from AI, questions are emerging around credit risk, cyber security vulnerabilities, and treating AI-generated assets or IP as debt collateral.

Mintz advised the underwriters in connection with Assembly Biosciences, Inc.’s underwritten offering of an aggregate of 5,591,840 shares of common stock and pre-funded warrants to purchase up to 1,040,820 shares of common stock, together with accompanying Class A and Class B warrants to purchase up to an aggregate of 6,632,660 shares of common stock at a combined price per share of common stock and accompanying Class A warrant and Class B warrant of $19.60 and a combined price per pre-funded warrant and accompanying Class A warrant and Class B warrant of $19.599. 

Agenda quoted Member Jacob Hupart in a recent article about the strategic questions audit committee members might consider asking their CFOs. The article notes the importance of monitoring key risks and opportunities, including ESG compliance and strategy, cybersecurity, data governance, and AI use.

Mintz advised the underwriters in connection with the $173 million public offering by Ondas Holdings Inc. of 53,084,000 shares of its common stock, which includes 6,924,000 shares of common stock sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock.

Mintz advised the lead placement agent in connection with an up to $50 million private placement by Equillium, Inc. The PIPE was comprised of (i) an initial upfront closing of approximately $30 million in gross proceeds in exchange for approximately 52.6 million shares of common stock (or, for certain investors, pre-funded warrants in lieu of common stock), and (ii) the potential for up to an additional $20 million in gross proceeds in exchange for up to approximately 35.1 million shares of common stock (or, for certain investors, pre-funded warrants in lieu of common stock), subject to achieving specified milestones related to clinical study initiation and share price.